Silk Road Medical, Inc. (NASDAQ:SILK) is reporting third quarter financial results on Tuesday 10th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, SILK is expected to report 3Q20 loss of $ 0.28 per share from revenue of $ 19.59 million.
For the full year, analysts anticipate top line of $ 76.79 million, while looking forward to loss of $ 1.12 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 92.00 million ~ $ 95.00 million
Click Here For More Historical Outlooks Of Silk Road Medical, Inc.
Previous Quarter Performance
Silk Road Medical, Inc. recorded loss for the second quarter of $ 0.32 per share, from the revenue of $ 15.09 million. The consensus estimates are loss of $ 0.37 per share from $ 9.46 million in revenue. The bottom line results beat street analysts by $ 0.05 or 13.51 percent, at the same time, top line results outshined analysts by $ 5.63 million or 59.51 percent.
Stock Performance
Shares of Silk Road Medical, Inc. traded low $ -1.75 or -2.50 percent on Monday, reaching $ 68.19 with volume of 404.50 thousand shares. Silk Road Medical, Inc. has traded high as $ 75.29 and has cracked $ 68.12 on the downward trend
According to the previous trading day, closing price of $ 68.19, representing a 235.60 % increase from the 52 week low of $ 20.84 and a 7.73 % decrease over the 52 week high of $ 75.80.
The company has a market capital of $ 2.30 billion and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 12th October 2020, maintained by SVB Leerink at Outperform rating, with $ 75.00 target price.
- On 1st October 2020, downgraded by Citigroup to Neutral from Buy rating.
Conference Call
Silk Road Medical, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website silkroadmed.com
Silk Road Medical, Inc. operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.
